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ABSTRACT
Objective: The Women’s Health Initiative hormone trials identified a 44% increase in ischemic
stroke risk with combination estrogen plus progestin and a 39% increase with estrogen alone.
We undertook a case-control biomarker study to elucidate underlying mechanisms, and to
potentially identify women who would be at lower or higher risk for stroke with
postmenopausal hormone therapy (HT).
Design: The hormone trials were randomized, double-blind, and placebo controlled.
Setting: The Women’s Health Initiative trials were conducted at 40 clinical centers in the
United States.
Participants: The trials enrolled 27,347 postmenopausal women, aged 50–79 y.
Interventions: We randomized 16,608 women with intact uterus to conjugated estrogens
0.625 mg with medroxyprogesterone acetate 2.5 mg daily or placebo, and 10,739 women with
prior hysterectomy to conjugated estrogens 0.625 mg daily or placebo.
Outcome Measures: Stroke was ascertained during 5.6 y of follow-up in the estrogen plus
progestin trial and 6.8 y of follow-up in the estrogen alone trial.
Results: No baseline clinical characteristics, including gene polymorphisms, identified women
for whom the stroke risk from HT was higher. Paradoxically, women with higher baseline levels
of some stroke-associated biomarkers had a lower risk of stroke when assigned to estrogen
plus progestin compared to placebo. For example, those with higher IL-6 were not at increased
stroke risk when assigned to estrogen plus progestin (odds ratio 1.28) but were when assigned
to placebo (odds ratio 3.47; p for difference¼0.02). Similar findings occurred for high baseline
PAP, leukocyte count, and D-dimer. However, only an interaction of D-dimer during follow-up
interaction with HT and stroke was marginally significant (p ¼ 0.03).
Conclusions: Biomarkers did not identify women at higher stroke risk with postmenopausal
HT. Some biomarkers appeared to identify women at lower stroke risk with estrogen plus
progestin, but these findings may be due to chance.
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PLoS CLINICAL TRIALSINTRODUCTION
The Women’s Health Initiative hormone trials were designed
to evaluate the role of postmenopausal hormone therapy
(HT) in cardiovascular risk reduction. Unexpectedly, both
estrogen with progestin and estrogen alone increased stroke
risk [1,2]. Evaluation of clinical characteristics and a limited
number of biomarkers in the individual trials [3,4] failed to
identify women at higher or lower risk for stroke with HT.
In this analysis, we pooled stroke outcomes from the
Women’s Health Initiative hormone trials to evaluate a broad
range of genetic and baseline phenotypic biomarkers in order
to formulate hypotheses about how HT increased stroke risk.
We evaluated the association between baseline biomarkers
and stroke, whether that association was modiﬁed by HT,
whether biomarkers were inﬂuenced by HT, and whether
biomarker changes inﬂuenced stroke risk.
The biomarkers analyzed in this paper were part of a
slightly larger panel of markers that were thought by
members of the Women’s Health Initiative laboratory work-
ing group to be associated with either stroke, venous
thrombotic disease, or myocardial infarction (MI). Before
analyzing the data we restricted our attention to those
markers for which we felt there was evidence for an
association with stroke, or for a modiﬁcation of the effects
on stroke in the presence of HT. Other markers in the
original panel were not analyzed in relation to stroke. The
major focus of this biomarker study was to understand why
HT increases stroke risk.
METHODS
Details of the design, recruitment, randomization, data
collection, intervention, and outcomes ascertainment proce-
dures of the Women’s Health Initiative hormone trials,
including CONSORT diagrams, have been published [1,2,5–
8]. Also see Figure 1.
Participants and Interventions
Between November 1993 and October 1998, postmenopausal
women with prior hysterectomy (n¼10,739) were randomized
to conjugated equine estrogens 0.625 mg/day (Premarin,
Wyeth Pharmaceticals, http://www.wyeth.com) or placebo;
those with an intact uterus (n ¼ 16,608) were randomized to
conjugated equine estrogens 0.625 mg/day with medroxypro-
gestrone acetate 2.5 mg/day (Prempro, Wyeth Pharmaceticals)
or placebo (Figure 1). Participants provided informed
consent in a form approved by local institutional review
Figure 1. Women’s Health Initiative Hormone Trials
CEE, conjugated equine estrogens; MPA, medroxyprogestrone acetate.
doi:10.1371/journal.pctr.0020028.g001
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Editorial Commentary
Background: The Women’s Health Initiative hormone trials originally set
out to evaluate whether postmenopausal hormone therapy (HT,
estrogen in the case of women who had had a hysterectomy, and
estrogen plus progestin for women who had not had a hysterectomy)
reduced the risk of heart attacks and strokes, as compared to placebo.
The trials were stopped early, and the investigators found that both
estrogen alone, as well as estrogen plus progestin increased the risk of
stroke amongst women participating in the trials. As part of a secondary
analysis of data from these trials, the investigators aimed to explore
possible associations between various biological markers (such as
variants in particular genes, and levels of particular lipids, proteins, and
other markers in blood), and the risk of a woman experiencing a stroke in
the trials. Specifically, they wanted to evaluate whether there was any
evidence for particular markers being associated with the risk of a stroke;
and then whether that risk was modified by whether a woman took HT
in the trials.
What the trial shows: In this study, the researchers collected early cases
of ischemic stroke in the trials (combining cases among women taking
estrogen with those for women taking both estrogen and progestin),
and matched these to control individuals, or women participating in the
trials who did not experience a stroke. Two hundred five women who
experienced a stroke were compared to 878 control individuals. The
markers analyzed included those for which there was already some
evidence for an association with stroke. Several clinical characteristics
and some biomarkers, as measured at the start of the trial, but none of
the gene variants, were linked with later risk of stroke. However, none of
these clinical characteristics or gene variants specifically identified
women who were at greater risk of experiencing a stroke within the HT
arms of the trial. High levels of two biomarkers, IL-6 and PAP, did seem to
identify women who were at lower risk of experiencing a stroke within
the HT arms of the trial. This finding is interesting, because high levels of
these markers had previously been suggested as being associated with a
higher risk of stroke. Levels of several biomarkers changed during the
trial, but for only one biomarker, D-dimer, did the change (an increase in
levels) seem to predict higher risk of stroke amongst women receiving
HT.
Strengths and limitations: A particular strength of this study includes
the nesting of a case-control study within the Women’s Health Initiative
trials, in which HT or placebo was randomly assigned. This design
minimizes the chance that individuals taking HT differ in their stroke risk
from individuals taking placebo. However, the power of this study to
detect anything other than large associations is limited; together with
the limitation of multiple statistical testing, the findings here must be
interpreted as hypotheses for further study and not definitive
conclusions.
Contribution to the evidence: This study adds data relating to possible
predictive risk markers for stroke among users of HT. The hypotheses
raised here remain to be tested in further studies.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.boards. The estrogen plus progestin arm was stopped after 5.6
y of follow-up upon recommendation of the Data and Safety
Monitoring Board because of increased breast cancer risk [1];
the estrogen alone trial was stopped after 6.8 y of follow-up
by the National Institutes of Health because of increased
stroke risk and lack of cardioprotection [2].
Because of early adverse effects of HT on cardiovascular
events in the Women’s Health Initiative a nested case-control
study was carried out. Participants with stroke, MI, and
venous thromboembolism (VTE) as of February 2001 were
matched to controls on age, randomization date, hysterec-
tomy status, and prevalent cerebrovascular disease. For this
paper we analyzed the cases of ischemic stroke, and the
combined controls for each of the three outcomes to
increase the power of detecting an association. In particular,
this study included 205 participants who had ischemic
strokes cases and 878 controls. Of the participants who had
a cases stroke, 11 also experienced an MI and seven also
experienced a VTE event by February 2001. Manuscripts
analyzing the biomarkers discussed in this paper in relation
to VTE and MI are in preparation. Participants provided
informed consent using forms approved by local institutional
review boards.
Outcomes
Follow-up and end-point determination. Clinical outcomes
were identiﬁed by semiannual questionnaires and classiﬁed
by centrally-trained local adjudicators following medical
record review [8]. All locally adjudicated stroke cases, and
self-reported strokes not validated by local adjudicators, were
centrally-adjudicated by stroke neurologists. All adjudicators
were blinded to treatment assignment. Ischemic strokes were
classiﬁed according to the Trial of Org 10172 in Acute Stroke
Therapy (TOAST) and Oxfordshire subtype classiﬁcations.
The TOAST stroke subtypes were as follows: large artery
artherosclerosis (9%), cardioembolic (12%), small vessel
occlusions (29%), other etiology (5%), and unknown etiology
(45%). The Oxfordshire classiﬁcations were as follows: total
anterior infarct (7%), partial anterior circulation infarct
(40%), lacunar infarction (37%), and posterior circulation
infarct (17%).
Genetic and biomarker analysis. Blood samples were
collected from all participants at baseline and 1 y. The
baseline blood samples were analyzed for all 205 participants
who experienced a stroke and 878 controls; the year 1 blood
was analyzed for the 138 participants who experienced their
stroke after the year 1 blood collection, and the 603 controls
who were matched to a participant who experiences her
stroke, MI, or VTE event after the year 1 blood collection.
Lipid proﬁles were analyzed in EDTA-treated plasma.
High-density lipoprotein (HDL) was precipitated with hep-
arin manganese (Dade-Behring, http://www.dadebehring.
com). interleukin-6 (IL-6, ultra-sensitive ELISA, R&D Systems,
http://www.rndsystems.com), E-selectin, and matrix metal-
loproteinase-9 (MMP-9) were measured at Medical Research
Laboratories (http://www.mrli.ppdi.com). C-reactive protein
(N-High Sensitivity CRP, Dade-Behring,), ﬁbrinogen (clot rate
assay: Diagnostica Stago, www.stago-us.com), factor VIII
activity (clotting time on mixing with factor VIII deﬁcient
plasma using STA-Deﬁcient VIII; Diagnostica Stago), von
Willebrand factor activity and ﬁbrin D-dimer (immunoturbi-
dometric assays: Liatest von Willebrand factor, Liatest D-Di;
Diagnostica Stago), plasminogen activator inhibitor-1 antigen
(PAI-1) and plasmin-antiplasmin complex (PAP, by in house
immunoassay [9,10]), prothrombin fragment 1.2 (ELISA,
Dade-Behring), and thrombin activatable ﬁbrinolysis inhib-
itor (TAFI; immunoassay with antibodies from Afﬁnity
Biologicals, http://www.afﬁnitybiologicals.com) were meas-
ured at the Laboratory for Clinical Biochemistry Research,
University of Vermont (http://www.med.uvm.edu/lcbr/
HP-DEPT.ASP?SiteAreaID¼513). Complete blood counts
were performed in clinics’ local laboratories. Genetic poly-
morphisms were assayed at Wake Forest University (http://
www.wfu.com); we assayed estrogen receptor 2-A1730G
(NCBI SNP identiﬁcation rs4986938), glycoprotein 1ba-
M145T (rs6065), glycoprotein IIIa–P1 (rs5918), and the Leiden
University (Factor V Leiden, thermolabile variant of MTHF,
PAI-1 4G/5G). No other biomarkers were analyzed for the
participants in this study.
Statistical Methods
All baseline marker values were log-transformed due to
skewed distributions and for consistency; differences from
baseline to year 1 were analyzed on the original scale. Logistic
regression models were controlled for age and study (estro-
gen alone or estrogen plus progestin), race, BMI, waist-hip
ratio, smoking, alcohol consumption, physical activity, dia-
betes mellitus, prevalent coronary disease (including six cases
of atrial ﬁbrillation), prevalent cerebrovascular disease, blood
pressure (BP), use of antihypertension medication, aspirin,
and statins at baseline. Analyses involving year 1 biomarker
data only involved 138 of 205 participants who experienced
their stroke after that analysis, and 603 (of 878) matched
controls.
We assessed the appropriateness of using biomarkers log
linearly in generalized additive models [11] using stroke as
response, correcting for risk factors; linearity was rejected for
CRP, TAFI, and platelets. For those markers we examined
both linear and quadratic models. While we used markers
linearly to assess signiﬁcance (the more powerful analysis), we
do not report the coefﬁcients in the logistic regression model,
but rather the more easily interpreted odds ratios (OR)
comparing quartiles or quintiles. Thus, there is no one-to-one
correspondence between p-values for models below 0.05 and
conﬁdence intervals for OR not containing 1.
Sensitivity analyses that excluded potential outliers were
carried out; except where noted, results were unaffected. All
analyses involving TAFI were repeated comparing the
subjects with TAFI values above the 90th percentile (7.4 lg/
ml) with those below the 25th percentile, as we a priori
hypothesized that only very high TAFI levels inﬂuence stroke
outcome. We only refer to this additional analysis where it
differs from the analysis of TAFI on a log linear scale. As most
strokes that were analyzed in this study happened early in the
trials, most subjects were adhering to study medication. Of
the 205 incident stroke cases in this study, only 32 out of 118
of the subjects on HT and 16 out of 87 subjects on placebo
were nonadherent 6 mo before their stroke.
RESULTS
Baseline Data
Baseline characteristics are shown by case-control status
(Table 1). As this study only included participants who had
www.plosclinicaltrials.org June | 2007 | e28 0003
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Table 1. Baseline Characteristics by Case-Control Status and Hormone Trial
Category Variable Parameter Estrogen Alone Trial Estrogen Plus Progestin Trial p-Value
a
Control
(n ¼ 365)
Hormone
(n ¼ 90)
Control
(n ¼ 513)
Hormones
(n ¼ 115)
Vital statistics, mean
(standard deviation)
Age at screening (y) 66.7 (6.5) 67.0 (6.7) 66.9 (6.9) 68.4 (6.2) 0.06
BMI (kg/m
2) 29.6 (5.7) 30.1 (5.6) 27.9 (5.4) 28.3 (5.2) 0.27
Waist-to-hip ratio 0.8 (0.1) 0.9 (0.2) 0.8 (0.1) 0.8 (0.1) ,0.001
Systolic BP (mm Hg) 131 (17) 139 (18) 130 (18) 138 (20) ,0.001
Diastolic BP (mm Hg) 76 (9) 78 (10) 75 (9) 76 (11) 0.04
Ethnicity, % White 75.6 78.9 88.3 86.1 0.93
Black 17.3 14.4 5.7 8.7
Other 7.1 6.7 6.0 5.2
Risk factors Alcohol (g/wk) 3.6 (7.9) 3.6 (7.8) 5.4 (11.5) 5.3 (12.6) 0.64
Physical activity (MET hrs/wk)
b 9.6 (11.7) 7.3 (8.6) 12.3 (14.7) 9.0 (9.9) 0.33
Risk factors, % Smoking status Never 52.0 45.5 56.1 46.5 0.07
Past 39.3 44.3 36.2 41.2
Current 8.7 10.2 7.7 12.3
Diabetes mellitus 7.4 12.2 4.9 13.9 ,0.001
Hypertension Never 57.8 30.0 65.5 51.0 ,0.001
Untreated 6.3 16.3 8.8 14.6
Treated 35.9 53.8 25.7 34.4
History of cardiovascular
disease
19.9 28.4 11.9 14.6 0.07
Baseline aspirin use, % 23.0 31.1 21.8 22.6 0.24
Baseline statin use 10.7 6.7 8.2 7.8 0.37
Gene Polymorphism Estrogen receptor
2-A1730G (rs4986938), %
CC 37.1 47.1 38.6 45.0 0.09
CT 49.7 44.7 47.4 43.2
TT 13.2 8.2 14.0 11.7
Factor V Leiden, % GG 96.4 95.4 95.2 93.6 0.52
GA 3.6 4.6 4.8 6.4
Glycoprotein 1ba-M145T
(rs6065), %
CC 75.1 77.6 85.0 81.8 0.87
CT 22.6 20.0 13.4 17.3
TT 2.3 2.4 1.6 0.9
Integrin alpha2–807, % CC 41.1 38.8 36.0 44.5 0.47
CT 46.0 42.4 48.8 42.7
TT 12.9 18.8 15.2 12.7
MTHFR, % CC 48.7 52.9 42.6 50.9 0.27
CT 42.0 39.1 44.2 35.5
TT 9.2 8.0 13.2 13.6
PAI-1, % 4G4G 20.7 23.5 25.2 27.8 0.29
4G5G 51.3 51.8 53.1 42.6
5G5G 28.0 24.7 21.8 29.6
Glycoprotein IIIa–P1
(rs5918), %
CC 3.4 2.4 2.7 1.8 0.28
CT 25.2 22.6 21.2 16.5
TT 71.3 75.0 76.1 81.7
Baseline biomarkers,
median (IQR)
Inflammation CRP (mg/l) 2.49 (3.56) 3.92 (4.01) 1.89 (3.48) 2.49 (4.30) ,0.001
E-Selectin (ng/ml) 45 (27) 46 (21) 43 (26) 49 (23) 0.007
IL-6 (pg/ml) 2.87 (2.4) 3.83 (2.48) 2.86 (2.20) 3.32 (2.20) ,0.001
MMP-9 (ng/ml) 220 (148) 271 (192) 218 (151) 236 (165) ,0.001
Lipids HDL-cholesterol (mmol/l) 1.35 (0.44) 1.27 (0.40) 1.40 (0.52) 1.30 (0.44) 0.002
HDL-2 (mmol/l) 0.36 (0.18) 0.34 (0.18) 0.36 (0.21) 0.34 (0.18) 0.19
HDL-3 (mmol/l) 0.97 (0.31) 0.89 (0.23) 1.01 (0.34) 0.92 (0.31) ,0.001
Lp(a) (mmol/l) 0.82 (1.21) 0.80 (1.00) 0.64 (1.00) 0.68 (1.00) 0.43
LDL-cholesterol (mmol/l) 3.65 (1.26) 3.74 (1.01) 3.57 (1.17) 3.73 (1.30) 0.02
Total Cholesterol (mmol/l) 5.91 (1.35) 5.91 (1.24) 5.72 (1.27) 5.85 (1.32) 0.11
Triglyceride (mmol/l) 1.60 (1.06) 1.81 (1.36) 1.49 (0.94) 1.50 (1.04) 0.03
Thrombosis and other
blood markers
D-Dimer (ng/ml) 0.32 (0.33) 0.37 (0.50) 0.32 (0.34) 0.47 (0.38) ,0.001
Fibrinogen (mg/l) 316 (123) 324 (86) 305 (111) 316 (126) 0.09
Factor VIII (%) 103 (68) 122 (94) 105 (63) 111 (79) 0.04
PAI-1 antigen (ng/ml) 44.3 (57.5) 48.4 (49.4) 35.6 (47.7) 42.5 (51.8) 0.14
PAP (nmol/l) 4.17 (2.10) 4.24 (2.35) 4.56 (2.52) 4.49 (2.42) 0.65
TAFI (lg/ml) 5.18 (2.60) 4.83 (1.94) 5.05 (2.42) 4.91 (2.34) 0.05
von Willebrand factor (%) 90 (55) 106 (55) 93 (54) 91 (51) 0.02
Prothrombin F1.2 (nmol/l) 1.29 (0.47) 1.28 (0.45) 1.29 (0.42) 1.29 (0.42) 0.90 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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treatment (unadjusted OR 1.53, 95% conﬁdence interval [CI]
1.01–2.32; adjusted for confounders OR 1.51, 95% CI 0.95–
2.38) was comparable to the full duration of the trials [3,4].
Of the 14 clinical characteristics, ﬁve were associated with
stroke (about one would be expected by chance); of the 23
biomarkers, 13 were associated with stroke (one or two would
be expected by chance); none of the seven polymorphisms
was associated with stroke. Among controls, Hardy-Weinberg
equilibrium was not rejected for any of the polymorphisms.
For all biomarkers we ﬁtted a model including an interaction
between biomarker and trial enrollment (estrogen alone or
estrogen plus progestin versus placebo). Of 30 biomarkers
and polymorphisms, only the interaction between hematocrit
and trial was marginally signiﬁcant (p ¼ 0.07). As one or two
signiﬁcant results would be expected by chance, this suggests
that there were no interaction effects between the trial
(estrogen plus progestin or estrogen alone) and the bio-
markers. This result, together with the fact that the overall
effects of HT on stroke were similar in both trials, suggests
that it was appropriate to combine the estrogen plus
progestin trial and the estrogen alone trial for analyses of
the effects of these biomarkers on stroke.
Outcomes and Estimation
Risk of ischemic stroke for biomarkers. For each baseline
biomarker the stroke risk was compared in multivariate
analyses (Table 2). For continuous biomarkers we used log-
linear models, and for the polymorphisms we used additive
genetic models. As continuous variables, IL-6 (p ¼ 0.02), CRP
(p ¼ 0.03), MMP-9 (p ¼ 0.004), D-dimer (p , 0.001), LDL (p ¼
0.03), von Willebrand factor (p¼0.10), and factor VIII activity
(p ¼ 0.10) were positively associated with stroke, whereas
HDL-3 was inversely associated (p ¼ 0.02) with stroke. Of the
30 biomarkers analyzed, seven had a statistically signiﬁcant
association with stroke at the level of p ¼ 0.05; one or two
markers would be expected to be signiﬁcant by chance. While
TAFI was not strongly associated with stroke when analyzed
as a continuous variable (p¼0.09), the OR of stroke for TAFI
above the 90th percentile compared to the lowest quartile
was 0.24 (95% CI 0.09–0.59; p ¼ 0.003). Several other
biomarkers showed less signiﬁcant associations.
Risk of ischemic stroke with baseline biomarkers by
treatment assignment. Of the 30 biomarkers studied, the p-
value for interaction between biomarker level and treatment
assignment in the pooled cohorts nearly reached signiﬁcance
for IL-6 (p¼0.06) and was signiﬁcant for PAP (p¼0.02) (Table
3). As one or two statistically signiﬁcant results are expected
by chance, these results may be due to chance. For these
markers, as well as D-dimer and the leukocyte count, the
pattern for the estrogen plus progestin trial suggested a
smaller OR associated with elevated biomarkers for the active
arm than the placebo arm of the trial; no such pattern was
observed in the estrogen alone trial. A post-hoc analysis
restricted to the estrogen plus progestin trial yielded the
following p-values for an interaction between baseline
biomarker and HT with stroke in the estrogen plus progestin
trial: IL-6 (p ¼ 0.02), PAP (p ¼ 0.002), D-dimer (p ¼ 0.02), and
leukocyte count (p ¼ 0.04), suggesting that individuals with
high levels of these biomarkers at baseline have lower stroke
.......................................................................................................................................................................................
.
Table 1. Continued.
Category Variable Parameter Estrogen Alone Trial Estrogen Plus Progestin Trial p-Value
a
Control
(n ¼ 365)
Hormone
(n ¼ 90)
Control
(n ¼ 513)
Hormones
(n ¼ 115)
Leukocyte Count (10
6 cells/l) 5.8 (2.1) 6.2 (1.7) 5.8 (1.9) 6.3 (2.2) ,0.001
Platelet count (Kcell/ml) 243 (69) 246 (64) 245 (82) 244 (65) 0.96
Hematocrit (%) 40.5 (3.8) 40.9 (4.4) 40.4 (3.8) 41.1 (4.3) 0.61
Homocysteine (umol/l) 8.29 (3.79) 8.48 (3.64) 8.08 (3.40) 8.61 (4.67) 0.18
ap-Value quantifies association of biomarker, polymorphism, or baseline characteristic with stroke from logistic regression models, controlling for treatment assignment (estrogen,
estrogen-placebo, estrogen plus progestin, estrogen plus progestin-placebo).
bMEThrs/wk, metabolic equivalent hours/week.
doi:10.1371/journal.pctr.0020028.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
.......................................................................................
Table 2. Risk of Ischemic Stroke for Baseline Biomarkers:
Highest Quartile versus Lowest Quartile
Category Biomarker OR
a (95% CI) p-Value
b
Inflammation CRP 1.72 (0.97–3.05) 0.03
E-selectin 1.27 (0.74–2.19) 0.25
IL-6 2.26 (1.30–3.91) 0.02
MMP-9 1.58 (0.97–2.58) 0.004
Lipids HDL-cholesterol 0.73 (0.44–1.22) 0.14
HDL-3 0.57 (0.34–0.97) 0.02
LDL-cholesterol 1.46 (0.88–2.41) 0.03
Triglyceride 1.54 (0.91–2.59) 0.52
Thrombosis and
other blood markers
D-dimer 2.53 (1.50–4.27) ,0.001
Fibrinogen 1.07 (0.72–1.71) 0.53
Factor VIII 1.62 (1.00–2.62) 0.10
TAFI 0.69 (0.42–1.15) 0.09
TAFI
c 0.24 (0.09–0.59) 0.003
von Willebrand factor 1.50 (0.91–2.47) 0.10
Leukocyte count 1.48 (0.88–2.48) 0.13
Polymorphism Estrogen receptor
2-A1730G (rs4986938)
0.26
TT versus CC 0.69 (0.39–1.22)
CT versus CC 0.74 (0.51–1.07)
Only results that were statistically significant in this analysis or had a p-value , 0.10 in
Table 1 are shown.
aOR is the comparison of the fourth quartile versus the first quartile, and is based on a
logistic regression model controlled for age, trial, race, BMI, waist-hip ratio, smoking,
alcohol consumption, physical activity, diabetes, history of cardiovascular disease,
systolic and diastolic BP, use of antihypertension medication, aspirin, and statin use.
bp-Value for biomarkers based on a logistic regression model using a 1 degree-of-
freedom test for biomarkers (log scale) and a 2 degree-of-freedom test for
polymorphism. Covariate adjustment same as above.
cComparison of the 90th percentile versus the 1st quartile.
doi:10.1371/journal.pctr.0020028.t002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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levels of these biomarkers.
We did not ﬁnd differences in biomarker by treatment
assignment between stroke subtypes. In particular, for these
results we found no signiﬁcant differences between ischemic
strokes being classiﬁed as large artery atherosclerosis or
cardioembolism and those classiﬁed as small vessel occlusion
(unpublished data).
Biomarker change from baseline to year 1. One-year
c h a n g e si nb i o m a r k e r sa r es h o w ni nT a b l e4 .S e v e r a l
inﬂammatory (p , 0.001 for CRP, E-selectin, and MMP-9)
and thrombotic biomarkers (p , 0.001 for PAI-1 and PAP)
were altered by HT, as were lipids (all p , 0.001). When we
removed ﬁve extreme changes in D-dimer, the p-value for
that marker changed from 0.02 to 0.005. No other outliers
had a substantial effect. Overall, 14 of the 20 biomarkers had
signiﬁcant changes from baseline to year 1, far more than the
one that would be expected by chance.
Risk of ischemic stroke by change in biomarker level from
baseline to year 1. One-year changes from baseline values
were associated with stroke risk in multivariate analysis for
only one biomarker: von Willebrand factor (lowest quintile of
change OR 0.66, 95% CI 0.35–1.23; middle quintile, including
no change, referent; highest quintile OR 0.95, 95% CI 0.51–
1.74; p ¼ 0.04).
Changes in biomarkers and the association of HT with
stroke. Of the 20 biomarkers measured at baseline and 1 y,
only the change in D-dimer demonstrated an interaction with
randomization assignment (p ¼ 0.03, Table 5). For women
whose D-dimer increased, the risk of stroke was higher with
HT (estrogen plus progestin and estrogen alone combined,
OR 1.38 for the top quintile of change) while for women
whose D-dimer decreased, the risk of stroke was lower (OR
0.49 for the bottom quintile).
We examined whether changes in biomarker level could be
considered an intermediate outcome on the pathway from
HT to ischemic stroke, in that inclusion of a biomarker
change in a regression model including treatment assignment
would signiﬁcantly reduce the association of HT with
ischemic stroke [12]. This was not the case for any marker.
DISCUSSION
Interpretation
This nested case-control study was undertaken to elucidate
mechanisms underlying the increased stroke risk with HT in
the Women’s Health Initiative clinical trials, and to attempt
to identify women at lower or higher risk for treatment-
related stroke. Baseline levels of several biomarkers repre-
senting inﬂammation and coagulation activity, but not the
genotypes that were studied here, were associated with
increased stroke risk. The ﬁnding that women with higher
IL-6, PAP, D-dimer, and leukocyte counts at baseline were at
lower risk for stroke if assigned to estrogen plus progestin
than placebo, but not estrogen alone, is counterintuitive and
is likely due to a noncausal association since both hormone
treatment groups had similar stroke rates. When one-year
changes in biomarkers were examined, only women with
treatment-related increases in D-dimer had increased stroke
risk with HT. The effect of other risk factors (such as BP,
hypertension, and smoking) in the complete Women’s Health
Initiative cohort has been previously reported [3,4].
The relatively small number of strokes limited our power to
.......................................................................................................................................................................................
Table 3. Ischemic Stroke Risk with Baseline Biomarker by Treatment Assignment
Category Biomarker Estrogen Alone Estrogen plus Progestin Interaction
p-Value
b
Estrogen
(46/187
a)
Placebo
(44/178
a)
Estrogen plus
Progestin (72/268
a)
Placebo
(43/245
a)
Inflammation C-reactive protein 1.77 (0.62–5.00) 1.26 (0.39–4.07) 1.47 (0.60–3.60) 2.58 (0.72–9.21) 0.56
E-selectin 0.53 (0.18–1.56) 0.82 (0.25–2.64) 1.76 (0.71–4.41) 2.90 (0.84–10.03) 0.15
Interleukin-6 2.55 (0.81–8.07) 2.98 (1.00–8.84) 1.28 (0.53–3.12) 3.47 (1.00–12.06) 0.06
MMP-9 4.18 (1.35–12.99) 1.88 (1.35–2.99) 0.87 (0.39–1.96) 1.38 (0.52–3.70) 0.89
Lipids LDL-cholesterol 1.87 (0.60–5.88) 0.72 (0.25–2.09) 1.76 (0.75–4.15) 1.72 (0.62–4.76) 0.14
HDL-cholesterol 0.77 (0.25–2.14) 0.48 (0.16–1.43) 0.91 (0.41–2.03) 0.61 (0.21–1.81) 0.28
HDL-3 0.42 (0.12–1.42) 0.24 (0.07–0.81) 0.86 (0.38–1.93) 0.64 (0.21–1.94) 0.24
Triglyceride 2.05 (0.68–6.17) 2.43 (0.76–7.78) 0.86 (0.38–1.97) 2.09 (0.65–6.74) 0.28
Thrombosis and
other blood markers
D-dimer 2.59 (0.87–7.71) 2.92 (1.02–8.39) 1.40 (0.60–3.24) 6.33 (1.67–24.01) 0.13
Fibrinogen 1.08 (0.37–3.15) 1.21 (0.42–3.47) 0.87 (0.38–1.96) 1.34 (0.52–3.45) 0.89
Factor VIII 3.11 (1.18–8.15) 1.62 (0.60–4.40) 0.92 (0.39–2.15) 1.53 (0.60–3.91) 0.96
PAP 1.73 (0.61–4.92) 1.55 (0.53–4.57) 0.32 (0.13–0.79) 7.09 (1.48–34.03) 0.02
TAFI 0.63 (0.19–2.06) 0.37 (0.12–1.12) 0.84 (0.36–2.00) 1.04 (0.38–2.84) 0.88
von Willebrand factor 1.79 (0.67–4.78) 1.58 (0.54–4.59) 1.23 (0.53–2.87) 1.63 (0.54–4.91) 0.47
Leukocyte count 2.78 (0.81–9.51) 1.94 (0.54–6.88) 0.70 (0.32–1.55) 3.09 (0.94–10.14) 0.33
Polymorphism Estrogen receptor
2-A1730G (rs4986938)
0.43
TT versus CC 0.39 (0.10–1.49) 0.76 (0.21–2.72) 0.65 (0.25–1.66) 1.18 (0.38–3.66)
CT versus CC 0.52 (0.24–1.13) 0.67 (0.30–1.48) 0.70 (0.37–1.31) 1.29 (0.59–2.80)
Values are OR (95% CI) comparing top to bottom quartile of each biomarker, and were derived from a logistic regression model controlling for age, trial, race, BMI, waist-hip ratio,
smoking, alcohol consumption, physical activity, diabetes, history of cardiovascular disease (including history of AF), systolic and diastolic BP, use of antihypertension medication,
aspirin, and statin. Only results that were statistically significant in this analysis or had a p-value   0.10 in Table 1 are shown.
aStrokes/controls.
bp-Value for the interaction of active treatment/placebo3 biomarker or polymorphism, based on a 1 degree-of-freedom test for biomarkers (log-scale) and 2 degrees-of-freedom for
polymorphism.
doi:10.1371/journal.pctr.0020028.t003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Although low-density lipoprotein (LDL)–cholesterol appears
to be a weak risk factor for ischemic stroke in women [13,14],
there was evidence in Women’s Health Initiative of a trend
toward lower stroke risk in women with a reduction in LDL–
cholesterol of 0.52–0.73 mmol/l on HT. HDL–cholesterol is
more strongly correlated with stroke risk in epidemiologic
studies, with protection at levels above 1.45 mmol/l in women
aged 45–64 y, and above 1.04 mmol/l in women over age 65 y
[13,14]. In this analysis, there was some evidence of a trend
.......................................................................................................................................................................................
Table 4. Changes in Biomarkers from Baseline to Year 1
Category Biomarker Estrogen Alone
Trial, Median (IQR)
Estrogen Plus Progestin
Trial, Median (IQR)
p-Value
a
Estrogen
(27/133)
b
Placebo
(33/121)
b
Estrogen Plus
Progestin (54/195)
b
Placebo
(24/154)
b
Inflammation CRP (mg/l) 2.87 (5.10) 0.11 (2.35) 1.68 (6.33) 0.64 (4.95) ,0.001
E-selectin (ng/ml)  7.2 (13.0)  0.5 (9.5)  8.4 (11.2) 0.2 (9.1) ,0.001
IL-6 (pg/ml) 0.29 (1.62) 0.06 (4.11) 0.49 (4.84) 0.05 (2.57) 0.13
MMP-9 (ng/ml) 29 (154)  23 (148) 52 (146) 9 (178) ,0.001
Lipids Total cholesterol (mmol/l)  0.40 (0.80)  0.02 (0.77)  0.42 (0.63)  0.05 (0.79) ,0.001
LDL-cholesterol (mmol/l)  0.74 (0.74)  0.00 (0.77)  0.57 (0.59)  0.05 (0.73) ,0.001
HDL-cholesterol (mmol/l) 0.19 (0.25) 0.00 (0.21) 0.12 (0.20) 0.01 (0.19) ,0.001
HDL-2 (mmol/l) 0.07 (0.12)  0.01 (0.12) 0.05 (0.10)  0.00 (0.09) ,0.001
HDL-3 (mmol/l) 0.12 (0.16) 0.00 (0.13) 0.06 (0.14) 0.01 (0.13) ,0.001
Lp(a) (mmol/l)  0.18 (0.32)  0.07 (0.45)  0.17 (0.32)  0.00 (0.35) ,0.001
Triglycerides (mmol/l) 0.30 (0.88)  0.02 (0.71) 0.08 (0.66)  0.00 (0.52) ,0.001
Thrombosis and
other blood markers
D-dimer (ng/ml) 0.15 (0.71)  0.01 (0.34) 0.20 (0.69) 0.08 (0.86) 0.03
Fibrinogen (mg/dl)  15.3 (70.2)  1.10 (71.5)  21.3 (68.7)  0.5 (68.4) 0.007
Factor VIII (%) 0.1 (33.2) 0.7 (30.5) 0.6 (33.3) 1.1 (32.7) 0.69
PAI-1 antigen (ng/ml)  12.2 (42.7) 2.5 (43.0)  3.8 (50.2)  2.0 (50.9) 0.001
PAP (nmol/l) 1.05 (1.70) 0.15 (1.59) 0.83 (2.08) 0.07 (1.94) ,0.001
TAFI (lg/ml) 0.25 (0.93)  0.06 (1.41)  0.01 (1.12)  0.02 (0.88) 0.09
von Willebrand factor (%)  0.3 (33.9) 2.8 (43.6)  2.0 (37.0) 2.5 (37.7) 0.08
Prothrombin F1.2 (nmol/l) 0.50 (3.13)  0.07 (2.53)  0.32 (0.78) 0.34 (2.56) 0.06
Homocysteine (lmol/l)  0.63 (2.69)  0.11 (2.18)  0.44 (2.11)  0.14 (2.44) 0.07
ap-Value from a paired t-test (per participant) of change in biomarker controlling for the same variables as in Table 2. For each participant the biomarker value at year 1 was compared
with the value at baseline for the same participant. Platelet count, hematocrit, and leukocyte count were not measured at year 1.
bStrokes/controls.
doi:10.1371/journal.pctr.0020028.t004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 5. Ischemic Stroke Risk by Treatment Assignment Modified by Change in Biomarker, Baseline to Year 1
Category Biomarker First Quintile of Change Fifth Quintile of Change Interaction p-Value
a
Change Value OR (95% CI) Change Value OR (95% CI)
Inflammation CRP (mg/l) , 0.6 0.83 (0.32–2.13) .3.1 1.28 (0.36–4.61) 0.56
E-selectin (ng/ml) , 11.0 1.67 (0.46–6.14) .3.0 0.59 (0.21–1.68) 0.26
IL-6 (pg/ml) , 0.9 1.12 (0.46–2.74) .1.0 0.68 (0.28–1.63) 0.69
MMP-9 (ng/ml) , 70 1.59 (0.63–4.02) .107 0.88 (0.34–2.30) 0.76
Lipids Total cholesterol (mmol/l) , 0.8 1.65 (0.60–4.50) .0.3 0.85 (0.31–2.38) 0.68
LDL-cholesterol (mmol/l) , 0.9 0.77 (0.26–2.31) .0.2 0.56 (0.14–2.26) 0.68
HDL-cholesterol (mmol/l) , 0.1 1.99 (0.70–5.65) .0.3 0.77 (0.23–2.64) 0.13
HDL-2 (mmol/l) , 0.1 2.35 (0.71–7.73) .0.4 0.44 (0.15–1.30) 0.30
HDL-3 (mmol/l) , 0.1 2.88 (0.99–8.44) .0.2 1.41 (0.40–4.98) 0.20
Lp(a) (mmol/l) , 0.3 1.74 (0.43–7.02) .0.1 0.95 (0.39–2.33) 0.92
Triglycerides (mmol/l) , 0.3 0.65 (0.26–1.63) .0.5 0.61 (0.22–1.66) 0.30
Thrombosis and
other blood markers
D-dimer (lg/ml) , 0.1 0.49 (0.19–1.28) .0.3 1.38 (0.48–3.92) 0.03
Fibrinogen (mg/dl) , 6.1 1.51 (0.54–4.21) .42 0.94 (0.41–2.17) 0.50
Factor VIII (%) , 18 1.38 (0.57–3.34) .21 1.29 (0.52–3.16) 0.88
PAI-1 antigen (ng/ml) , 24.4 1.58 (0.54–4.63) .14.3 1.11 (0.45–2.74) 0.93
PAP (nmol/l) , 0.5 0.66 (0.22–1.95) .1.6 2.37 (0.60–9.31) 0.46
TAFI (lg/ml) , 0.4 1.13 (0.42–3.03) .0.6 0.88 (0.34–2.23) 0.57
von Willebrand factor (%) , 22 0.45 (0.17–1.15) .0.2 2.04 (0.83–5.02) 0.23
Prothrombin F1.2 (nmol/l) , 0.2 1.21 (0.49–3.00) .0.4 0.99 (0.34–2.85) 0.95
Homocysteine (lmol/l) , 1.7 1.28 (0.47–3.48) .1.1 2.10 (0.82–5.36) 0.52
ap-Value for interaction of active treatment/placebo 3 biomarker change is based on a 1 degree-of-freedom test for change in biomarker.
doi:10.1371/journal.pctr.0020028.t005 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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0.16 mmol/l (12%) increase in HDL–cholesterol on HT.
Baseline HDL-3, but not HDL-2, appeared to be protective
against stroke, perhaps explaining the lack of signiﬁcance for
HDL–cholesterol overall.
Inﬂammation promotes atherogenic events, including
stroke [15,16]. IL-6 is an important regulator of the CRP gene
[17]. HT with estrogen alone or estrogen plus progestin
increases CRP to a similar extent [18]. The rise in CRP with
estrogen plus progestin, but not estrogen alone, appears to be
IL-6 mediated [19]. These observations suggest that estrogen
plus progestin and estrogen alone have differing proinﬂam-
matory effects, consistent with the signiﬁcant interaction
between baseline levels of IL-6 and stroke risk that we
identiﬁedwithestrogenplusprogestin,butnotestrogenalone.
It has been hypothesized that hemostatic activation under-
lies increased vascular risk with hormones, and it has been
previously reported that hormones raise D-dimer levels [20].
Most associations of hemostatic markers and stroke were
carried out during acute ischemic stroke, which itself affects
the hemostatic system. A prospective study in patients with
prior transient ischemic attack or asymptomatic carotid
bruits identiﬁed prothrombin fragment 1.2, but not PAP or
D-dimer, as an independent predictor of subsequent cardi-
ovascular events [21]. In contrast, D-dimer levels independ-
ently predicted ischemic stroke in healthy men, whereas
prothrombin fragment 1.2 did not [22]. Our ﬁndings of
higher D-dimer as a risk marker for stroke, and that increases
in D-dimer with HT might identify women at risk of stroke,
support a role for hemostatic activation in the development
of stroke.
Generalizability
The strengths of this analysis are the ability to prospectively
assess the interaction between randomly assigned HT and
baseline biomarker levels and changes in biomarker levels.
Some limitations should be considered. There were a
relatively small number of strokes, conﬁning us to detecting
relatively large interactions of treatment with biomarkers.
Because we analyzed a large number of biomarkers, some of
the results may be due to chance. We studied clinical trial
participants who may be different from the general pop-
ulation, so that the results might not be generalizable. A
standardized diagnostic approach to stroke was not followed,
and this may have led to misclassiﬁcation of stroke types.
Information on stroke subtype was limited. The fact that
stroke risk was increased similarly with estrogen alone and
estrogen plus progestin, whereas baseline levels of four
biomarkers (IL-6, PAP, D-dimer, leukocyte count) appeared
to predict a protective association from estrogen plus
progestin, raises concerns about the plausibility of these
ﬁndings. Regarding the ﬁndings related to change in D-dimer
and stroke susceptibility of women with HT, in view of the
number of markers, one interaction might be expected by
chance.
Overall Summary
In this nested case-control study, no biomarker convincingly
predicted the stroke risk seen with HT, although some
hypotheses were raised. A genome-wide scan is in progress to
search for underlying mechanisms, and a proteome study has
been proposed to characterize hormone-induced proteins.
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